RxDoctor Payments Data

Helen Parke, NP

Family · Lynchburg, VANPI 1821507526

Payments from drug & device makers

$1,552in general payments, 2019–2025

Across 52 payments — averaging $29.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$314
  • Bayer$212
  • Abbott$197
  • SK Life Science, Inc.$185
  • Novo Nordisk$151
  • AbbVie$135
  • plus $358 from 8 others

What the payments were for

  • Food & beverage$1,552100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,552 in reported general payments places this provider in the 75th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$1,436
Medicare patients
57
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide38$68,240
FarxigaDapagliflozin Propanediol32$43,325
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$19,873
LinzessLinaclotide12$18,586
TrulicityDulaglutide15$18,431
EliquisApixaban11$14,066
Aripiprazole12$4,876
Albuterol Sulfate HfaAlbuterol Sulfate50$2,278
Diclofenac Sodium29$2,250
Pregabalin29$2,140
Icosapent Ethyl12$2,066
Gabapentin74$1,713
Duloxetine Hcl64$1,706
Omeprazole96$1,406
Atorvastatin Calcium119$1,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$151$68,24038 claims
AstraZenecaFarxiga$314$43,32532 claims
AbbVieLinzess, Synthroid$135$19,16826 claims
Lilly USA, LLCTrulicity$53$18,43115 claims
PfizerEliquis$54$14,06611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,332 family providers in Virginia.

Other family in Lynchburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →